Published in PLoS One on February 13, 2013
Tumour heterogeneity in the clinic. Nature (2013) 3.92
Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment. Acta Pharmacol Sin (2015) 0.99
Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives. Onco Targets Ther (2014) 0.91
Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases. J Pathol Transl Med (2016) 0.88
Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody. J Biol Chem (2015) 0.87
Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis? J Transl Med (2014) 0.85
Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer. Oncotarget (2016) 0.85
Impact of EGFR mutation status on tumor response and progression free survival after first-line chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis. J Thorac Dis (2014) 0.83
Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative. Oncotarget (2016) 0.80
EGFR mutation heterogeneity and mixed response to EGFR tyrosine kinase inhibitors of non small cell lung cancer: a clue to overcoming resistance. Transl Lung Cancer Res (2013) 0.79
A sensitive and practical method to detect the T790M mutation in the epidermal growth factor receptor. Oncol Lett (2016) 0.78
High efficiency vortex trapping of circulating tumor cells. Biomicrofluidics (2015) 0.77
Plasminogen activator inhibitor-1 enhances radioresistance and aggressiveness of non-small cell lung cancer cells. Oncotarget (2016) 0.77
Prevalence and clinical significance of BRAF V600E in Chinese patients with lung adenocarcinoma. Thorac Cancer (2015) 0.76
Exploring the impact of EGFR T790M neighboring SNPs on ARMS-based T790M mutation assay. Oncol Lett (2016) 0.75
Analysis of EGFR mutation status in tissue and plasma for predicting response to EGFR-TKIs in advanced non-small-cell lung cancer. Oncol Lett (2017) 0.75
Comprehensive profiling and quantitation of oncogenic mutations in non small-cell lung carcinoma using single molecule amplification and re-sequencing technology. Oncotarget (2016) 0.75
Clinical outcome of epidermal growth factor receptor-tyrosine kinase inhibitors therapy for patients with overlapping kirsten rat sarcoma 2 viral oncogene homolog and epidermal growth factor receptor gene mutations. Thorac Cancer (2015) 0.75
High concordance of ALK rearrangement between primary tumor and paired metastatic lymph node in patients with lung adenocarcinoma. J Thorac Dis (2016) 0.75
The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations. Medicine (Baltimore) (2016) 0.75
Three-Dimensional Patient-Derived In Vitro Sarcoma Models: Promising Tools for Improving Clinical Tumor Management. Front Oncol (2017) 0.75
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst (2005) 9.10
The new World Health Organization classification of lung tumours. Eur Respir J (2001) 6.91
Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell (2011) 6.43
The new lung cancer staging system. Chest (2009) 6.30
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol (2007) 5.55
Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell (2012) 5.44
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest (2008) 4.95
Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol (2009) 3.58
Mechanisms of tumor progression. Cancer Res (1986) 2.62
Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol (2011) 2.34
Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol (2012) 2.31
Metapopulation dynamics and spatial heterogeneity in cancer. Proc Natl Acad Sci U S A (2002) 2.17
Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci (2008) 2.17
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res (2010) 2.05
Genetic heterogeneity and cancer drug resistance. Lancet Oncol (2012) 1.91
Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst (1998) 1.81
EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol (2012) 1.71
Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br J Cancer (2007) 1.55
Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours. Lung Cancer (2008) 1.31
Genetic heterogeneity in ductal carcinoma of the breast. Lab Invest (2000) 1.08
Personalized targeted therapy for lung cancer. Int J Mol Sci (2012) 1.02
Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas. Dis Esophagus (2007) 0.96
Detection of epidermal growth factor receptor variations by partially denaturing HPLC. Clin Chem (2006) 0.92
Molecular evolution and intratumor heterogeneity by topographic compartments in muscle-invasive transitional cell carcinoma of the urinary bladder. Lab Invest (2000) 0.86
Epidermal growth factor receptor mutations in female patients with postoperative recurrent non-small-cell lung cancer. J Cancer Res Ther (2012) 0.80
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol (2011) 18.34
RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med (2003) 7.37
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet (2011) 5.73
Emergence of fatal PRRSV variants: unparalleled outbreaks of atypical PRRS in China and molecular dissection of the unique hallmark. PLoS One (2007) 5.60
Unsupervised pattern discovery in human chromatin structure through genomic segmentation. Nat Methods (2012) 4.89
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol (2013) 4.20
Single-cell RNA-Seq profiling of human preimplantation embryos and embryonic stem cells. Nat Struct Mol Biol (2013) 4.04
Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol (2009) 3.58
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol (2010) 3.30
Crystal structure of the cytoskeleton-associated protein glycine-rich (CAP-Gly) domain. J Biol Chem (2002) 3.01
Detecting cAMP-induced Epac activation by fluorescence resonance energy transfer: Epac as a novel cAMP indicator. EMBO Rep (2004) 2.98
Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol (2012) 2.98
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol (2013) 2.94
Nanowires for enhanced boiling heat transfer. Nano Lett (2009) 2.82
Atmospheric new particle formation enhanced by organic acids. Science (2004) 2.62
Complex hemodynamics at the apex of an arterial bifurcation induces vascular remodeling resembling cerebral aneurysm initiation. Stroke (2007) 2.58
Chinese herbal formulas for treating hypertension in traditional Chinese medicine: perspective of modern science. Hypertens Res (2013) 2.55
Tet1 regulates adult hippocampal neurogenesis and cognition. Cell Stem Cell (2013) 2.40
Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis (2008) 2.31
Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol (2012) 2.31
An ancient transcription factor initiates the burst of piRNA production during early meiosis in mouse testes. Mol Cell (2013) 2.23
Association between the various mutations in viral core promoter region to different stages of hepatitis B, ranging of asymptomatic carrier state to hepatocellular carcinoma. Am J Gastroenterol (2010) 2.20
Antagonistic HLH/bHLH transcription factors mediate brassinosteroid regulation of cell elongation and plant development in rice and Arabidopsis. Plant Cell (2009) 2.17
Genomic binding profiles of functionally distinct RNA polymerase III transcription complexes in human cells. Nat Struct Mol Biol (2010) 2.15
Functional analysis of transcription factor binding sites in human promoters. Genome Biol (2012) 2.12
Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proc Natl Acad Sci U S A (2013) 2.09
Cellular pharmacology studies of shikonin derivatives. Phytother Res (2002) 2.09
Developmental regulation and individual differences of neuronal H3K4me3 epigenomes in the prefrontal cortex. Proc Natl Acad Sci U S A (2010) 2.06
Dominant negative pathogenesis by mutant proinsulin in the Akita diabetic mouse. Diabetes (2003) 2.05
c-Myc-mediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma. Hepatology (2014) 2.04
Cross-platform comparison of SYBR Green real-time PCR with TaqMan PCR, microarrays and other gene expression measurement technologies evaluated in the MicroArray Quality Control (MAQC) study. BMC Genomics (2008) 1.99
Central nervous system imprinting of the G protein G(s)alpha and its role in metabolic regulation. Cell Metab (2009) 1.98
Prevalence of the metabolic syndrome and its relation to cardiovascular disease in an elderly Chinese population. J Am Coll Cardiol (2006) 1.98
Rap1 regulates E-cadherin-mediated cell-cell adhesion. J Biol Chem (2004) 1.98
The scaffold protein Homer1b/c links metabotropic glutamate receptor 5 to extracellular signal-regulated protein kinase cascades in neurons. J Neurosci (2005) 1.97
A novel nuclear factor-kappaB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status. Clin Cancer Res (2007) 1.96
Podocyte-specific overexpression of the antioxidant metallothionein reduces diabetic nephropathy. J Am Soc Nephrol (2008) 1.94
Escherichia coli: development of carbapenem resistance during therapy. Clin Infect Dis (2005) 1.89
Role of pancreatic stellate cells in pancreatic cancer metastasis. Am J Pathol (2010) 1.87
Development of heart failure in chronic hypertensive Dahl rats: focus on heart failure with preserved ejection fraction. Hypertension (2006) 1.87
PPARG, KCNJ11, CDKAL1, CDKN2A-CDKN2B, IDE-KIF11-HHEX, IGF2BP2 and SLC30A8 are associated with type 2 diabetes in a Chinese population. PLoS One (2009) 1.86
Toll-like receptor 3 mediates establishment of an antiviral state against hepatitis C virus in hepatoma cells. J Virol (2009) 1.85
Epigenetic signatures of autism: trimethylated H3K4 landscapes in prefrontal neurons. Arch Gen Psychiatry (2011) 1.81
Heterotypic piRNA Ping-Pong requires qin, a protein with both E3 ligase and Tudor domains. Mol Cell (2011) 1.79
PKA phosphorylation activates the calcium release channel (ryanodine receptor) in skeletal muscle: defective regulation in heart failure. J Cell Biol (2003) 1.78
Organization of the Caenorhabditis elegans small non-coding transcriptome: genomic features, biogenesis, and expression. Genome Res (2005) 1.77
Adaptation to P element transposon invasion in Drosophila melanogaster. Cell (2011) 1.76
Protein kinase A phosphorylation of the cardiac calcium release channel (ryanodine receptor) in normal and failing hearts. Role of phosphatases and response to isoproterenol. J Biol Chem (2002) 1.73
The cell growth suppressor, mir-126, targets IRS-1. Biochem Biophys Res Commun (2008) 1.73
Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia. Eur J Immunol (2010) 1.72
A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause (2003) 1.71
Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J Exp Med (2010) 1.70
High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma. Hum Pathol (2012) 1.70
Emodin enhances cytotoxicity of chemotherapeutic drugs in prostate cancer cells: the mechanisms involve ROS-mediated suppression of multidrug resistance and hypoxia inducible factor-1. Cancer Biol Ther (2007) 1.70
NONCODE v2.0: decoding the non-coding. Nucleic Acids Res (2007) 1.69
Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation. Ann Neurol (2011) 1.67
Formation of nanoparticles of blue haze enhanced by anthropogenic pollution. Proc Natl Acad Sci U S A (2009) 1.67
Deubiquitinating and interferon antagonism activities of coronavirus papain-like proteases. J Virol (2010) 1.64
The impact of angiotensin-converting enzyme inhibitor therapy on the extracellular collagen matrix during left ventricular assist device support in patients with end-stage heart failure. J Am Coll Cardiol (2007) 1.63
Nkx3.1 and Myc crossregulate shared target genes in mouse and human prostate tumorigenesis. J Clin Invest (2012) 1.63
Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. PLoS One (2013) 1.57
MR diffusion tensor imaging study of postinfarct myocardium structural remodeling in a porcine model. Magn Reson Med (2007) 1.57
A journey to Semantic Web query federation in the life sciences. BMC Bioinformatics (2009) 1.56
Surgical treatment strategies in chronic pancreatitis: a meta-analysis. Arch Surg (2012) 1.54
Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord (2010) 1.54
ECM1 controls T(H)2 cell egress from lymph nodes through re-expression of S1P(1). Nat Immunol (2011) 1.54
Mechanisms of heart failure with well preserved ejection fraction in dogs following limited coronary microembolization. Cardiovasc Res (2004) 1.53
UAP56 couples piRNA clusters to the perinuclear transposon silencing machinery. Cell (2012) 1.53
The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. Pain (2007) 1.53
Single-beat estimation of end-diastolic pressure-volume relationship: a novel method with potential for noninvasive application. Am J Physiol Heart Circ Physiol (2006) 1.50
MiR-26a enhances metastasis potential of lung cancer cells via AKT pathway by targeting PTEN. Biochim Biophys Acta (2012) 1.48
Mapping the C. elegans noncoding transcriptome with a whole-genome tiling microarray. Genome Res (2007) 1.46
Short- and long-term outcomes after laparoscopic and open hepatectomy for hepatocellular carcinoma: a global systematic review and meta-analysis. Ann Surg Oncol (2012) 1.46
Transvenous phrenic nerve stimulation in patients with Cheyne-Stokes respiration and congestive heart failure: a safety and proof-of-concept study. Chest (2012) 1.43
Preparation and evaluation of a novel glass-ionomer cement with antibacterial functions. Dent Mater (2011) 1.43
A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord (2009) 1.42
A model system for mapping vascular responses to complex hemodynamics at arterial bifurcations in vivo. Neurosurgery (2006) 1.41
Dofetilide enhances the contractility of rat ventricular myocytes via augmentation of Na+-Ca 2+ exchange. Cardiovasc Drugs Ther (2009) 1.41
Direct quantification of fusion rate reveals a distal role for AS160 in insulin-stimulated fusion of GLUT4 storage vesicles. J Biol Chem (2007) 1.40